Women's Health Market Report 2026

The women's health market size has grown strongly in recent years. It will grow from $45.36 billion in 2025 to $48.19 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing prevalence of chronic conditions among women, expansion of gynecological healthcare services, rising awareness of women-specific diseases, growth in pharmaceutical research activities, improved access to healthcare facilities.

The women's health market size is expected to see strong growth in the next few years. It will grow to $60.99 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing investments in women-focused drug development, rising demand for personalized treatment plans, expansion of early screening programs, growing adoption of digital health integration, increasing focus on long-term women’s health management. Major trends in the forecast period include increasing development of targeted therapies for women, rising adoption of precision medicine approaches, growing use of advanced diagnostic tools, expansion of non-hormonal treatment options, enhanced focus on preventive women’s healthcare.

The increasing prevalence of women-centric diseases is expected to drive the growth of the women’s health market going forward. Women-centric diseases such as anemia, osteoporosis, breast cancer, menopause-related conditions, and others are becoming more common due to several risk factors, including family history, advancing age, early onset of menstruation, menopause after the age of 55, obesity, and other contributing factors. This growing prevalence of women-centric diseases is increasing the demand for women’s health products and services needed to treat these conditions and support the overall health and well-being of women. For instance, in January 2023, the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, reported that cervical cancer was once among the leading causes of cancer-related deaths in American women. Approximately 13,960 new cases of invasive cervical cancer were expected to be diagnosed in the United States in 2023, with around 4,310 women projected to die from the disease. Therefore, the rising prevalence of women-centric diseases is driving the growth of the women’s health market.

Major companies operating in the women’s health market are introducing new technologies to maintain their market position, such as transcutaneous electrical nerve stimulation (TENS) technology. Transcutaneous Electrical Nerve Stimulation (TENS) is a non-invasive therapeutic technique that uses a small, battery-operated device to deliver low-voltage electrical currents to targeted areas of the body through electrode pads placed on the skin. For instance, in September 2023, Myoovi, a UK-based provider of menstrual pain solutions, launched a TENS-based technology to help manage painful menstrual cramps. TENS generates electrical signals that disrupt and block pain signals before they reach the brain, thereby reducing discomfort. This technology offers women a drug-free alternative for managing menstrual pain.

In March 2024, Halma, a UK-based technology company, acquired Rovers Medical Devices for $92.63 million. This acquisition expands Halma’s portfolio in the women’s health sector, particularly in cervical cancer diagnostics, and aligns with its strategy to strengthen its position in cancer diagnostic solutions. Rovers Medical Devices is a Netherlands-based company specializing in the design and manufacture of sample collection devices for the diagnosis and prevention of cervical cancer.

Major companies operating in the women's health market are AbbVie Inc., Bayer AG, Merck & Co Inc., Pfizer Inc., Agile Therapeutics, Novartis AG, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Ferring Pharmaceuticals, Lupin Pharmaceuticals Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Hologic Inc., Celmatix Inc., HERA Biotech Inc., Maven Clinic Inc., MobileODT Ltd., ObsEva SA, Syrona Health AG.

North America was the largest region in the women's health market in 2025. Asia-Pacific is expected to be the fastest-growing region in the women's health market report during the forecast period. The regions covered in the women's health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the women's health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the women’s health market by increasing costs of imported pharmaceutical ingredients, diagnostic devices, medical equipment, and specialized healthcare technologies. Hospitals, pharmaceutical manufacturers, and diagnostic providers in North America and Europe are most affected due to globalized supply chains, while Asia-Pacific faces pricing pressure on exported medical products. These tariffs are increasing treatment costs and slowing technology adoption. At the same time, they are supporting domestic drug manufacturing, regional clinical research, and localized production of women’s health devices.

The women's health market research report is one of a series of new reports that provides women's health market statistics, including women's health industry global market size, regional shares, competitors with a women's health market share, detailed women's health market segments, market trends and opportunities, and any further data you may need to thrive in the women's health industry. This women's health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Women’s health refers to the field of medicine and healthcare that concentrates on the diagnosis, treatment, and prevention of diseases and conditions that specifically affect women. It covers a broad range of concerns, including reproductive health, menstrual health, pregnancy and childbirth, menopause, and conditions such as breast and ovarian cancers. It also addresses other health issues that disproportionately impact women, including osteoporosis, cardiovascular disease, and autoimmune disorders.

The primary types of products for women’s health include devices, drugs, and pharmaceutical pipelines. Women’s health devices are medical tools used to treat diseases and conditions affecting women. Women aged 50 years and older, along with other age groups, receive hormonal treatments, non-hormonal treatments, and surgical interventions for various applications, including postmenopausal osteoporosis, hormonal infertility, endometriosis, uterine fibroids, contraception, menopause, and polycystic ovary syndrome (PCOS). These products and treatments are distributed through multiple channels, such as hospitals, retail stores, and online pharmacies.

The women's health market consists of revenues earned by entities by providing hormone therapy, birth control treatment, and other related services. The market value includes the value of related goods sold by the service provider or included within the service offering. The women's health market also includes sales of contraceptive devices and pharmaceuticals, densitometry, breast implants, obstetrics or gynaecology biopsy, imaging devices, and drugs such as Xgeva, Evista, Mirena, Zometa, Reclast, and Class, among others, that are used in providing women's health services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.